Document is current

Article History

Received: 26 January 2024

Accepted: 7 October 2024

First Online: 16 October 2024

Declarations

:

: The study was approved by the relevant ethics committees (ethical approval number: 234/2014BO1: first approval on June 17 2014, approval of Amendment 1 on June 11 2015, approval of Amendment 2 on March 18 2019; Ethics Committee of the Medical Faculty, University of Tübingen, Tübingen, Germany). All patients included in the study provided informed consent. All experiments were performed in accordance with relevant guidelines and regulations.

: Not applicable.

: ADH: has received honoraria from Roche, Novartis, Lilly, MSD, AstraZeneca, Seagen, GSK, Exact Science, Riemser, Teva, Onkowissen, Gilead, Stemline Therapeutics, Pfizer, Amgen, Pierre Fabre and Eisai and travel support from Roche, Novartis, Lilly, AstraZeneca, GSK, Exact Science, Gilead, Stemline Therapeutics and Pfizer. MW: received speaker honoraria from AstraZeneca, Celgene, Roche, MSD and Novartis. H-CK: has received honoraria from Pfizer, Novartis, Roche, Genomic Health/Exact Sciences, Amgen, AstraZeneca, Riemser, Carl Zeiss Meditec, TEVA, Theraclion, Janssen-Cilag, GSK, LIV Pharma, Lily, SurgVision, Onkowissen, Gilead, Daiichi Sankyo and MSD, travel support from Carl Zeiss Meditec, LIV Pharma, Novartis, Amgen, Pfizer, Daiichi Sankyo, Tesaro, Gilead and Stemline Therapeutics and owns stock of Theraclion SA. PH: has received honoraria from Amgen, Novartis, Hexal and Pfizer. HT: has received honoraria from Novartis, Roche, Celgene, Teva, and Pfizer, and travel support from Roche, Celgene and Pfizer. JE: has received honoraria/travel support from Roche, Celgene, Novartis, Pfizer, Lilly, Pierre Fabre, Teva, and Tesaro, AstraZeneca, Daiichi Sankyo, Seagen, Gilead, Stemline Therapeutics, ClinSol. DL: has received honoraria from Amgen, Loreal, Pfizer, Novartis, Eli Lilly, Samsung, Celgene, Astra Zeneca, Teva and GSK. VM: has received speaker honoraria from AstraZeneca, Daiichi Sankyo, Eisai, Pfizer, MSD, Medac, Novartis, Roche, Seagen, Onkowissen, high5 Oncology, Medscape, Gilead, Pierre Fabre, iMED Institut. Has received consultancy honoraria from Roche, Pierre Fabre, PINK, ClinSol, Novartis, MSD, Daiichi Sankyo, Eisai, Lilly, Seagen, Gilead, Stemline Therapeutics. Has received institutional research support from Novartis, Roche, Seagen, Genentech, AstraZeneca. Has received travel grants from AstraZeneca, Roche, Pfizer, Daiichi Sankyo, Gilead. LLM: received honoraria from Amgen, AstraZeneca, Celgene, Gilead, Lilly, MSD, Novartis, Pfizer, Roche and Eisai for advisory boards, lectures and travel support. EB: has received honoraria from Novartis, Celgene, Eisai, Daiichi Sankyo, Merrimack, AstraZeneca, Riemser, Pfizer, Hexal, Amgen, and onkowissen.de for consulting, clinical research management, or medical education activities. PW: has received honoraria from Roche, Novartis, Amgen, AstraZeneca, Pfizer, MSD, Clovis, Tesaro, Celgene, Teva, Eisai, Daiichi Sankyo, Seagen and Eli Lilly. CH: has received honoraria from Amgen, Celgene, Oncovis, Roche, and Pfizer. HH: received speaker honoraria from: Novartis Pharma GmbH and LEO Pharma GmbH and grant/research support from: Novartis Pharma GmbH. CCH: received honoraria from AstraZeneca, Daiichi Sankyo, Eisai, Novartis, Pfizer, Roche, Gilead and MSD as well as support for attending meetings from Daiichi Sankyo. CK: has received honoraria from Amgen, Roche, Teva, Novartis, MSD, Axios, and Riemser. PAF: has received honoraria from Roche, Pfizer, Novartis, and Celgene; his institution conducts research for Novartis. RW: has received honoraria from Agendia, Amgen, APOGHEVA, Aristo, AstraZeneca, Celgene, Clovis Oncology, Daiichi Sankyo, Eisai, Esteve, Exact Sciences, Gilead, GSK, Hexal, Lilly, Medstrom Medical, MSD, Mundipharma, Mylan, Nanostring, Novartis, Odonate, Paxman, Palleos, Pfizer, Pierre Fabre, PINK, Puma Biotechnolgogy, Riemser, Roche, Sandoz/Hexal, Sanofi Genzyme, Seattle Genetics/Seagen, Sidekick, Stemline Therapeutics, Tesaro Bio, Teva, Veracyte, Viatris, Wiley, FOMF, Aurikamed, ClinSol, Pomme Med, medconcept, MCI, MediSeminar. MU: has received honoraria for advisory boards and travel support, payed to the employer from Abbvie, Amgen, AstraZeneca, BMS, Celgene, Daiichi Sankyo, Eisai, Lilly Deutschland, Lilly Int., MSD, Mundipharma, Myriad Genetics, Odonate, Pfizer, Puma Biotechnology, Roche, Sanofi Aventis Deutschland, Teva Pharmaceuticals Ind Ltd, Novartis, Pierre Fabre, Clovis Oncology, and Seattle Genetics. WJ: as received honoraria and research grants from Sanofi-Aventis, Novartis, Lilly, Pfizer, Roche, Chugai, AstraZeneca, MSD, and Daiichi Sankyo. F-AT: has received speaker and consultancy honoraria from AstraZeneca, Gilead, GSK, MSD, Novartis, Onkowissen, Pfizer, Roche. MPL: has received honoraria from Lilly, Pfizer, Roche, MSD, Hexal, Novartis, AstraZeneca, Eisai, Exact Sciences, Agendia, Daiichi Sankyo, Grünenthal, Gilead, Pierre Fabre, PharmaMar, Samantree, Endomag, and medac for advisory boards, lectures, and travel support. SYB: received honoraria from Roche, Novartis, Pfizer, MSD, Teva, AstraZeneca. TNF: received honoraria from Novartis, Roche, Pfizer, TEVA, Daiichi Sankyo, AstraZeneca and MSD. AS: has received honoraria from Roche, Celgene, AstraZeneca, Novartis, Pfizer, Zuckschwerdt Verlag GmbH, Georg Thieme Verlag, Aurikamed GmbH, MCI Deutschland GmbH, bsh medical communications GmbH, and promedicis GmbH. All remaining authors have nothing to declare.